Back to top
more

Viking Therapeutics (VKTX)

(Real Time Quote from BATS)

$66.18 USD

66.18
25,050,130

-6.70 (-9.19%)

Updated Nov 4, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

by Zacks Equity Research

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

by Zacks Equity Research

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today

by Zacks Equity Research

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound

by Zacks Equity Research

Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen

by Zacks Equity Research

Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.

Sundeep Ganoria headshot

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

by Sundeep Ganoria

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?

by Zacks Equity Research

Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.

Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies

by Zacks Equity Research

Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.

Brian Bolan headshot

Brian Big Idea On Technical Analysis

by Brian Bolan

A look at three stocks where technical analysis can help and the TAZR service.

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.

Viking (VKTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

by Zacks Equity Research

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $71.67, indicating a -1.59% shift from the previous trading day.

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

by Zacks Equity Research

SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

2 Top Biotech Buyout Candidates

by Andrew Rocco

The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

Ekta Bagri headshot

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

by Ekta Bagri

Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data

by Zacks Equity Research

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics

by Zacks Equity Research

Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

Time to be "Overweight" Viking Therapeutics

by Andrew Rocco

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

by Zacks Equity Research

Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

by Zacks Equity Research

Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.

Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study

by Zacks Equity Research

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data

by Zacks Equity Research

Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.